Wolfgang Miesbach: Translating Gene Therapy into Haemophilia Care at EHA 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Honoured to be speaking at EHA 2026 this Friday, 12 June in the ‘Gene engineering and therapy’ session.
In ‘Translating Genetic Innovation into Haemophilia Care’ (P141-2), I’ll explore how three decades of gene therapy development are reshaping not just treatment, but how care itself is organised — from the structure of treatment centres to the way we follow patients across their lifetimes.
Haemophilia has long been a proving ground for genetic medicine, and the lessons here ripple out to many other conditions.
I’ll also reflect on a sobering reality: some gene therapies are being pulled from the market not because they failed patients, but because the business model did.
The future of genetic medicine may depend less on what we can cure than on what our systems are willing to pay for.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 18, 2026, 19:53Astha Thakkar: What Is the Most Important Test for a Bleeding Disorder?
-
Jun 18, 2026, 19:53Shehab Mohamed: Real-World Evidence on Maternal and Neonatal Outcomes in ITP
-
Jun 18, 2026, 19:51Mawadda Chukr: What 10 Randomized Trials Reveal About Novel ITP Therapies
-
Jun 18, 2026, 19:49Ana Rita Santos: Cost-Effectiveness of Chatbot-Supported Remote Monitoring for Anticoagulation Management
-
Jun 18, 2026, 19:46Angela Fan: Highlighting the Significant Burden Faced by Patients Living With PV
-
Jun 18, 2026, 15:29Santagata Davide: Timely Removal of Retrievable IVC Filters May Reduce VTE Recurrence and Mortality
-
Jun 18, 2026, 15:13Youssef Afifi: The Thrombocytosis–Bleeding Paradox
-
Jun 18, 2026, 15:06Nihala Sharin E A: The Vital Role of Hematology in the Medical Laboratory
-
Jun 18, 2026, 14:59Maeve Crowley: Shining a Light on Venous Thromboembolism Trends in Ireland